RecruitingPhase 3

Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients

China200 participantsStarted 2016-01-01

Plain-language summary

To evaluate: The radiographic progression-free survival (rPFS) of metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with androgen deprivation therapy (ADT) + second-generation antiandrogens±chemotherapy combined with cytoreductive prostatectomy (CRP)

Who can participate

Age range18 Years – 75 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male aged ≥18 and ≤75;
✓. Histologically confirmed prostate adenocarcinoma;
✓. Evidence of metastasis confirmed by magnetic resonance imaging (MRI)/computed tomography (CT) scan, bone scan, or histology;
✓. Clinical stage M1a (distant lymph node positive), M1b (bone metastasis), or M1c (visceral organ metastasis);
✓. Prostate cancer has not received local treatment (e.g., prostate radiotherapy, cryotherapy, etc.);
✓. The surgeon believes the prostate can be removed;

Exclusion criteria

✕. The surgeon believes the disease is unresectable;
✕. Life expectancy less than 2 years;
✕. Active spinal cord compression;
✕. History of prior local treatment for prostate cancer;
✕. Difficulty swallowing, chronic diarrhea, intestinal obstruction, and other factors affecting drug intake and absorption;
✕. Refusal to sign the informed consent;
✕. Investigator believes the individual is not suitable for inclusion.

What they're measuring

rPFS

Timeframe: 3 year

Trial details

NCT IDNCT06350825

SponsorThe First Affiliated Hospital with Nanjing Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-12-31

Contact for this trial

Lixin Hua, M.D.

13072564303 hlx5858@163.com

View on ClinicalTrials.gov More Metastatic Prostate Cancer trials